The report highlights Hanmi Pharm's commitment to sustainability, with key achievements including a ""AAA"" CP grade from the Fair Trade Commission, the highest ESG rating among domestic pharmaceutical companies, and significant investments in R&D. The report also details the company's efforts to develop new drugs, including for rare diseases, and to enhance its production facilities. Additionally, the report showcases Hanmi Pharm's social responsibility initiatives, such as supporting healthcare organizations, promoting employee well-being, and engaging in environmental sustainability.
Issuing Company Hanmi Pharm. Co., Ltd.
Report Type Sustainability Report
Report Language EN
Report Filesize 2.98 MB
No. of Pages 49 pages
Reporting periodJanuary 1 to December 31, 2020
Report Edition4
Assurance Provider Korea Standards Association
Reporting Standards GRI; AA1000AS v3
Materiality Assessmenttrue